DK1071745T3 - Fremgangsmåde til syntetisering af COX-2-inhibitorer - Google Patents

Fremgangsmåde til syntetisering af COX-2-inhibitorer

Info

Publication number
DK1071745T3
DK1071745T3 DK99918706T DK99918706T DK1071745T3 DK 1071745 T3 DK1071745 T3 DK 1071745T3 DK 99918706 T DK99918706 T DK 99918706T DK 99918706 T DK99918706 T DK 99918706T DK 1071745 T3 DK1071745 T3 DK 1071745T3
Authority
DK
Denmark
Prior art keywords
inhibitors
cox
synthesizing
synthesizing cox
Prior art date
Application number
DK99918706T
Other languages
English (en)
Inventor
Robert D Larsen
Philip J Pye
Kai Rossen
Edward G Corley
Ian W Davies
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of DK1071745T3 publication Critical patent/DK1071745T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61Halogen atoms or nitro radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/02Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups
    • C07C251/30Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having nitrogen atoms of imino groups quaternised
DK99918706T 1998-04-24 1999-04-20 Fremgangsmåde til syntetisering af COX-2-inhibitorer DK1071745T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8288898P 1998-04-24 1998-04-24
US8566898P 1998-05-15 1998-05-15
EP99918706A EP1071745B1 (en) 1998-04-24 1999-04-20 Process for synthesizing cox-2 inhibitors

Publications (1)

Publication Number Publication Date
DK1071745T3 true DK1071745T3 (da) 2004-11-29

Family

ID=26767964

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99918706T DK1071745T3 (da) 1998-04-24 1999-04-20 Fremgangsmåde til syntetisering af COX-2-inhibitorer

Country Status (28)

Country Link
US (2) US6040319A (da)
EP (1) EP1071745B1 (da)
JP (2) JP3325264B2 (da)
KR (1) KR100414998B1 (da)
CN (1) CN1178658C (da)
AR (1) AR015279A1 (da)
AT (1) ATE272613T1 (da)
AU (1) AU759469B2 (da)
BR (2) BRPI9917739B8 (da)
CA (1) CA2329193C (da)
CZ (1) CZ292515B6 (da)
DE (1) DE69919151T2 (da)
DK (1) DK1071745T3 (da)
EA (1) EA002975B1 (da)
ES (1) ES2226378T3 (da)
HK (1) HK1031399A1 (da)
HR (1) HRP20000722B1 (da)
HU (1) HU227627B1 (da)
IL (2) IL139127A0 (da)
NZ (1) NZ507597A (da)
PL (1) PL193248B1 (da)
PT (1) PT1071745E (da)
RS (1) RS49945B (da)
SI (1) SI1071745T1 (da)
SK (1) SK284805B6 (da)
TW (1) TW474934B (da)
UA (1) UA57143C2 (da)
WO (1) WO1999055830A2 (da)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861419A (en) * 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
KR100446324B1 (ko) 1999-01-14 2004-08-30 론자 아게 1-(6-메틸피리딘-3-일)-2-[4-(메틸술포닐)페닐]에타논 및이의 제조 방법
HUP0105124A3 (en) * 1999-01-14 2002-05-28 Merck & Co Inc 1-(6-methylpyridine-3-yl)-2-[4-(methylsulfonyl)phenyl]ethanone and method for its preparation
JP2001115963A (ja) 1999-10-13 2001-04-27 Daikin Ind Ltd 圧縮機
US6858631B1 (en) 1999-11-29 2005-02-22 Merck & Co., Inc. Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl
WO2001037833A1 (en) * 1999-11-29 2001-05-31 Merck Frosst Canada & Co. Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl
SK12672001A3 (sk) * 1999-12-08 2002-04-04 Pharmacia Corporation Zloženia inhibítora cyklooxygenázy-2 s rýchlym nástupom terapeutického účinku
JP2001261653A (ja) * 2000-03-17 2001-09-26 Sankio Chemical Co Ltd ピリジン誘導体の合成法
PH12001001175B1 (en) * 2000-05-26 2006-08-10 Merck Sharp & Dohme 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- (2,3')bipyridinyl in pure crystalline form and process for synthesis
US6521642B2 (en) 2000-05-26 2003-02-18 Merck & Co., Inc. 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl in pure crystalline form and process for synthesis
US6800647B2 (en) 2000-05-26 2004-10-05 Merck & Co., Inc. 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3]bipyridinyl in pure crystalline form and process for synthesis
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
AU5754701A (en) * 2000-07-13 2002-01-30 Pharmacia Corp Method of using cox-2 inhibitors in the treatment and prevention of ocular cox-2mediated disorders
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
PE20021017A1 (es) 2001-04-03 2002-11-24 Pharmacia Corp Composicion parenteral reconstituible
WO2002089798A2 (en) * 2001-05-04 2002-11-14 Merck & Co., Inc. Method and compositions for treating migraines
UA80682C2 (en) * 2001-08-06 2007-10-25 Pharmacia Corp Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
JP4700916B2 (ja) * 2004-02-02 2011-06-15 富士フイルムファインケミカルズ株式会社 ピリジン誘導体の製造方法
US7271383B2 (en) * 2004-08-11 2007-09-18 Lexmark International, Inc. Scanning system with feedback for a MEMS oscillating scanner
US20080096927A1 (en) 2004-08-24 2008-04-24 Simon Thomas J Combination Therapy for Treating Cyclooxygenase-2 Mediated Diseases or Conditions in Patients at Risk of Thrombotic Cardiovascular Events
WO2008091530A2 (en) * 2007-01-19 2008-07-31 Mallinckrodt Inc. Diagnostic and therapeutic cyclooxygenase-2 binding ligands
DK2401253T3 (da) 2009-02-27 2016-04-18 Cadila Healthcare Ltd Fremgangsmåde til fremstilling af etoricoxib
EP2582690B1 (en) 2010-06-16 2018-07-25 Glenmark Generics Limited Process for preparation of 2, 3-diaryl-5-substituted pyridines and their intermediates
MY163379A (en) 2010-11-15 2017-09-15 Virdev Intermediates Pvt Ltd A process for cyclooxygenase-2 selective inhibitor
ITMI20110362A1 (it) 2011-03-09 2012-09-10 F I S Fabbrica Italiana Sint P A Procedimento per la preparazione di 1-(6-metilpiridin-3-il)-2-[4-(metilsolfonil)fenil]etanone, un intermedio dell'etoricoxib.
SI2714676T1 (sl) 2011-05-27 2019-06-28 Farma Grs, D.O.O. Postopek za pripravo polimorfne oblike I etorikoksiba
ITMI20111455A1 (it) 2011-07-29 2013-01-30 Italiana Sint Spa Nuovo procedimento per la preparazione di 1-(6-metilpiridin-3-il)-2-[4-(metilsolfonil)fenil]etanone, un intermedio dell'etoricoxib.
CN103204803A (zh) 2012-01-13 2013-07-17 阿尔弗雷德·E·蒂芬巴赫尔有限责任两合公司 用于合成依托考昔的方法
ITMI20120394A1 (it) * 2012-03-14 2013-09-15 Zach System Spa Processo di sintesi di un chetosolfone derivato
WO2013144977A2 (en) 2012-03-30 2013-10-03 Mylan Laboratories Ltd. An improved process for the preparation of etoricoxib
GR1007973B (el) * 2012-06-26 2013-09-12 Φαρματεν Αβεε, Νεα ν-οξοιμινο παραγωγα ως ενδιαμεσα μιας βελτιωμενης μεθοδου παρασκευης 2,3-διαρυλο-5-υποκατεστημενων πυριδινων
WO2014033526A1 (en) 2012-08-27 2014-03-06 Cadila Healthcare Limited Pharmaceutical compositions of etoricoxib
ITVI20130014A1 (it) 2013-01-22 2014-07-23 Italiana Sint Spa Procedimento molto efficiente per preparare un intermedio di etoricoxib
WO2014114352A1 (en) * 2013-01-25 2014-07-31 Synthon Bv Process for making etoricoxib
CN104418799A (zh) * 2013-09-03 2015-03-18 天津药物研究院 一种依托考昔的晶型及其制备方法和应用
WO2015036550A1 (en) 2013-09-13 2015-03-19 Synthon B.V. Process for making etoricoxib
US10500178B2 (en) 2015-03-13 2019-12-10 The Board Of Trustees Of The Leland Stanford Junior University LTB4 inhibition to prevent and treat human lymphedema
CN104817473A (zh) * 2015-03-27 2015-08-05 南京大学 1-二甲氨基-3-二甲亚胺基-2-氯丙烯高氯酸盐在制备依托考昔中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA988522A (en) * 1972-05-05 1976-05-04 Haydn W.R. Williams 1,8-naphthyridine compounds
DE3842062A1 (de) * 1988-12-14 1990-06-28 Hoechst Ag Explosionssichere 1-dimethylamino-3-dimethylimino-2-arylpropen-1-salze, verfahren zu ihrer herstellung und ihre verwendung
US5861419A (en) * 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
CN1152863C (zh) * 1996-07-18 2004-06-09 麦克弗罗斯特(加拿大)公司 作为环氧合酶-2选择性抑制剂的取代的吡啶类化合物及其组合物

Also Published As

Publication number Publication date
AR015279A1 (es) 2001-04-18
US6252116B1 (en) 2001-06-26
CN1306425A (zh) 2001-08-01
WO1999055830A2 (en) 1999-11-04
BRPI9917739B1 (pt) 2016-05-03
BR9909844A (pt) 2001-04-03
CA2329193C (en) 2007-01-23
DE69919151D1 (de) 2004-09-09
CA2329193A1 (en) 1999-11-04
HUP0101407A2 (hu) 2001-09-28
EP1071745A2 (en) 2001-01-31
BRPI9917739B8 (pt) 2021-05-25
PL344108A1 (en) 2001-09-24
PL193248B1 (pl) 2007-01-31
PT1071745E (pt) 2004-11-30
RS49945B (sr) 2008-09-29
CN1178658C (zh) 2004-12-08
AU3655799A (en) 1999-11-16
AU759469B2 (en) 2003-04-17
TW474934B (en) 2002-02-01
JP3834263B2 (ja) 2006-10-18
WO1999055830A3 (en) 1999-12-29
SK284805B6 (sk) 2005-11-03
DE69919151T2 (de) 2005-07-28
JP3325264B2 (ja) 2002-09-17
YU64100A (sh) 2002-11-15
HU227627B1 (en) 2011-10-28
NZ507597A (en) 2004-02-27
KR100414998B1 (ko) 2004-01-13
HK1031399A1 (en) 2001-06-15
JP2002513035A (ja) 2002-05-08
UA57143C2 (uk) 2003-06-16
BR9909844B1 (pt) 2010-10-19
HUP0101407A3 (en) 2002-12-28
SK15892000A3 (sk) 2001-07-10
JP2003040852A (ja) 2003-02-13
EP1071745B1 (en) 2004-08-04
EA200001102A1 (ru) 2001-04-23
HRP20000722A2 (en) 2001-06-30
HRP20000722B1 (en) 2009-07-31
EP1071745A4 (en) 2002-05-15
KR20010042941A (ko) 2001-05-25
US6040319A (en) 2000-03-21
EA002975B1 (ru) 2002-12-26
ATE272613T1 (de) 2004-08-15
CZ292515B6 (cs) 2003-10-15
IL139127A (en) 2006-07-05
SI1071745T1 (en) 2004-10-31
IL139127A0 (en) 2001-11-25
CZ20003940A3 (en) 2001-06-13
ES2226378T3 (es) 2005-03-16

Similar Documents

Publication Publication Date Title
DK1071745T3 (da) Fremgangsmåde til syntetisering af COX-2-inhibitorer
DK1016836T3 (da) Fremgangsmåde til tilvejebringelse af köling
DK1080348T3 (da) Fremgangsmåde til detektering af farver
FI980464A (fi) Menetelmä kuvakkeen muodostamiseksi
DK1011309T3 (da) Fremgangsmåde til tilvejebringelse af forøget fotosyntese
DK1364057T3 (da) Fremgangsmåde til detektion af ligander
DE69906311D1 (de) Diarylbenzopyranderivate als cyclooxygenase-2-inhibitoren
DK0856697T3 (da) Fremgangsmåde til foring af rør
IS5772A (is) Þalazín (phthalazine) afleiður af fosfódíesterasa4 lötum
DK1230247T3 (da) Fremgangsmåde til stabilisering af siloxanforbindelser
NO20010674D0 (no) Forbedret fremgangsmåte for to-bölgefelts-forsterkning
DK1142990T3 (da) Fremgangsmåde til fremstilling af transglutaminase
ID28577A (id) Metoda pemilihan waktu kalibrasi
DK0987356T3 (da) Fremgangsmåde til trækning
DK1294659T3 (da) Fremgangsmåde til isolering af katamin
ID27364A (id) Metode untuk menghambat mrp1
DK0864564T3 (da) Særlig fremgangsmåde til fremstillingen af alfa-bromlactamderivater
DK0749677T3 (da) Fremgangsmåde til fremskaffelse af data
DK0801070T3 (da) Fremgangsmåde til fremstilling af platinforbindelse
ID26804A (id) Metode untuk menghambat mrp1
DK1053474T3 (da) Fremgangsmåde til bestemmelse af prostetiske infektioner
DE69931084D1 (de) Verfahren zur Spurverfolgungsregelung
DK0981950T3 (da) Fremgangsm,åde til formering af phyllocactus
DK0934786T4 (da) Fremgangsmåde til strengstøbning af metal samt strengstøbeanlæg hertil
DK1051831T3 (da) Fremgangsmåde til tilvejebringelse af en adressefortegnelse